EUCTR2016-004420-29-Outside-EU/EEA进行中（未招募）1 期
A Phase 2, Open-label, Controlled, Multi-Center Extension Study to Evaluate 4-Year Antibody Persistence and Booster Response Fol-lowing MenABCWY Vaccination in Healthy Adolescents and Young Adults who Previously Participated in Studies V102_02 (NCT01210885) and V102_02E1 (NCT01367158). - MENABCWY-004 BST:002 (V102_02E2)
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 171
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Individuals who received either 2 doses of MenABCWY+OMV or a single dose of MenACWY followed by a dose of placebo, with the last study vaccine given approximately 48 to 56 months before study V102_02E2 (NCT01367158), who received Tdap only in V102_02E1 (NCT01367158) study and who received no other meningococcal vaccines;
- •A proportional number of subjects in each site aged 15 through 23 years on the day of informed consent/assent who did not participate in the V102_02 (NCT01210885) study and have not previously received any meningococcal vaccine.
- •Individuals who /whose parent(s)/legal guardian(s) have vol-untarily given written informed consent/assent after the nature of the study has been explained according to local regulatory requirements, prior to study entry.
- •Individuals who can comply with study procedures including blood draws and follow-up.
- •Females of non-childbearing potential
- •Females of childbearing potential who are not pregnant or breastfeeding and who are using an effective birth control method which they have used for at least 30 days prior to study entry, and which they intend to use for at least 30 days after the last study vaccination.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 171
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range 171
排除标准
- •History of any meningococcal vaccine administration (study group C)
- •History of any meningococcal vaccine administration other than vaccination given in the parent V102_02 (NCT01210885) study (study groups A and B).
- •Progressive, unstable or uncontrolled clinical conditions.
- •Hypersensitivity, including allergy, to any component of vaccines (including diphtheria toxoid (CRM197) and latex) whose use is foreseen in this study.
- •Clinical conditions representing a contraindication to intra-muscular vaccination and blood draws.
- •Abnormal function of the immune system resulting from:
- •Clinical conditions.
- •Systemic administration of corticosteroids (PO/IV/IM) for more than 14 consecutive days within 90 days prior to enrollment.
- •Administration of antineoplastic and immunomodulating agents or radiotherapy within 90 days prior to informed consent.
- •Received immunoglobulins or any blood products within 90 days prior to enrollment.
- •Received an investigational or non-registered medicinal product within 30 days prior to enrollment.
- •Received any other vaccines within 14 days (for inactivated vaccines) or 28 days (for live vaccines) prior to enrolment in this study or who are planning to receive any vaccine within 14 days from the study vaccines.
- •Study personnel as an immediate family or household mem-ber.
- •Who have experienced a moderate or severe acute infection and/or fever (defined as temperature >= 38°C) within 3 days prior to enrollment.
- •Who have received systemic antibiotic treatment within 3 days prior to enrollment.
- •Any other clinical condition that, in the opinion of the investigator, might interfere with the results of the study or pose additional risk to the subject due to participation in the study.
研究者
相似试验
进行中（未招募）
不适用
A Phase 2, Open-label, Controlled, Multi-center Study to Evaluate Meningococcal ACWY Antibody Response in Children Aged 40 and 60 Months who Have Previously Received Novartis MenACWY Conjugate Vaccine as Infantsovartis Meningococcal ACWY Conjugate Vaccine is intended for prevention of meningitidis and septicemia caused by Neisseria meningitidis serogroups A, C, W-135 and Y.EUCTR2007-004978-16-GBovartis Vaccines and Diagnostics S.r.l.476
进行中（未招募）
不适用
A Phase 2, Multi-center, Uncontrolled, Open-label Trial to Evaluate Safety, tolerability, and Efficacy of Orally Administered OPC-67683 as 100 mg BID with optional titration to 200 mg BID for up to Six Months Exposure in Patients with Pulmonary Multi-drug Resistant TuberculosisEUCTR2008-005107-26-LVOtsuka Pharmaceutical Development and Commercialization, Inc.430
进行中（未招募）
不适用
A Phase 2, Multi-center, Uncontrolled, Open-label Trial to Evaluate Safety, tolerability, and Efficacy of Orally Administered OPC-67683 as 100 mg BID with optional titration to 200 mg BID for up to Six Months Exposure in Patients with Pulmonary Multi-drug Resistant TuberculosisPulmonary Multidrug-resistant Tuberculosis (MDR TB)MedDRA version: 9.1Level: LLTClassification code 10037440Term: Pulmonary tuberculosisEUCTR2008-005107-26-EEOtsuka Pharmaceutical Development and Commercialization, Inc.430
进行中（未招募）
1 期
A Study to investigate Bavituximab in combination with Pembrolizumab in patients with advanced gastric or gastroesophageal cancer.EUCTR2019-000949-13-GBOncXerna Therapeutics, Inc.80
招募中
2 期
A Phase II study of M119102 for alopecia areataAlopecia AreataJPRN-jRCT2061220077Tomoyuki Nishiura25